GHRP-6: A Comprehensive Research Monograph

Overview

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide with the amino acid sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of approximately 873.01 Da. It belongs to the family of growth hormone secretagogues (GHSs) — synthetic compounds that stimulate growth hormone (GH) release from the anterior pituitary through a mechanism distinct from that of endogenous growth hormone-releasing hormone (GHRH). GHRP-6 was among the earliest synthetic GH secretagogues developed, originating from the pioneering work of Cyril Bowers and Frank Momany in the late 1970s and early 1980s, who discovered that modified met-enkephalin analogs could stimulate GH secretion through an unidentified receptor pathway.

The significance of GHRP-6 extends far beyond its role as a GH secretagogue. Research on GHRP-6 and related peptides was directly responsible for one of the most important discoveries in modern endocrinology: the identification and cloning of the growth hormone secretagogue receptor (GHS-R1a) by Howard and colleagues in 1996, and the subsequent discovery of its endogenous ligand, ghrelin, by Kojima and colleagues in 1999. GHRP-6 thus occupies a foundational position in the history of the ghrelin system, a hormonal network now understood to play central roles in GH regulation, appetite control, energy metabolism, cardiovascular function, and neuroprotection.

Structurally, GHRP-6 incorporates two unnatural D-amino acids (D-Trp at position 2 and D-Phe at position 5) that confer significant resistance to proteolytic degradation compared to natural peptide sequences. The C-terminal amidation further enhances stability. These structural features, combined with its relatively small size, allow GHRP-6 to be active via multiple routes of administration including intravenous, subcutaneous, and oral delivery. Beyond its GH-releasing activity, GHRP-6 has demonstrated a remarkably broad spectrum of cytoprotective effects in preclinical models, including cardioprotection, hepatoprotection, neuroprotection, wound healing enhancement, and prevention of multiple organ failure, establishing it as a compound of significant research interest across multiple biomedical disciplines.

Mechanism of Action

GHRP-6 exerts its biological effects through a dual-receptor mechanism involving the growth hormone secretagogue receptor type 1a (GHS-R1a) and the CD36 scavenger receptor. Its primary GH-releasing action operates through pathways that are complementary to, yet fundamentally distinct from, those of endogenous GHRH.

GHS-R1a Receptor Activation and GH Release

The primary mechanism by which GHRP-6 stimulates GH secretion involves binding to GHS-R1a, a G-protein-coupled receptor expressed in the anterior pituitary somatotrophs and in key hypothalamic nuclei including the arcuate nucleus (ARC) and ventromedial nucleus (VMN). The receptor was first cloned by Howard and colleagues in 1996, a breakthrough made possible directly by GHRP-6 pharmacology.

At the pituitary level, GHRP-6 activates GHS-R1a on somatotrophs to trigger intracellular calcium influx, which is essential for GH exocytosis. Notably, Wu and colleagues demonstrated that GHRP-6 stimulates GH release from pituitary cells without increasing intracellular cAMP levels, in contrast to both GHRH and the related peptide GHRP-2, which do elevate cAMP. This finding established that GHRP-6 operates through a calcium-dependent, cAMP-independent signaling cascade at the pituitary, mechanistically distinguishing it from GHRH-driven GH secretion.

However, the dominant site of GHRP-6 action is the hypothalamus rather than the pituitary. Popovic and colleagues provided critical evidence for this by demonstrating that patients with hypothalamopituitary disconnection showed a complete blockade of GHRP-6-induced GH secretion, while their response to GHRH remained intact. Furthermore, the striking synergistic effect observed when GHRP-6 and GHRH are co-administered in normal subjects — producing GH responses significantly greater than the arithmetic sum of individual responses — was entirely abolished in disconnected patients. These findings established that GHRP-6 primarily acts at the hypothalamic level, where it stimulates endogenous GHRH release while simultaneously suppressing somatostatin tone.

Hypothalamic Regulation of GHRH and Somatostatin

GHRP-6 modulates the two principal hypothalamic regulators of GH secretion in complementary directions. Argente and colleagues demonstrated that chronic GHRP-6 treatment in dwarf rats stimulated GHRH mRNA levels in the posterior arcuate nucleus while simultaneously decreasing somatostatin mRNA levels in the posterior periventricular nucleus. This dual action — enhancing the stimulatory GHRH signal while attenuating the inhibitory somatostatin signal — provides a mechanistic explanation for the potent and synergistic GH-releasing activity observed in vivo.

Bennett and colleagues further characterized hypothalamic GHS-R expression patterns, finding prominent GHS-R mRNA in the arcuate and ventromedial nuclei, with expression levels highly sensitive to circulating GH concentrations. GHS-R expression was markedly elevated in GH-deficient dwarf rats and normalized by exogenous GH replacement, suggesting a feedback mechanism whereby low GH states upregulate the receptor to enhance sensitivity to secretagogue stimulation.

CD36-Mediated Cytoprotective Pathways

Beyond GHS-R1a, GHRP-6 also binds to CD36, a multi-ligand scavenger receptor expressed abundantly in macrophages, endothelial cells, cardiac myocytes, hepatocytes, and wound granulation tissue. Through CD36 agonism, GHRP-6 activates PPARgamma signaling and attenuates the expression of pro-inflammatory and pro-fibrotic cytokines. This receptor pathway is thought to be the primary mediator of GHRP-6’s anti-fibrotic and wound healing effects, which are largely independent of its GH-releasing activity.

Pharmacokinetics

GHRP-6 pharmacokinetics have been characterized in both animal models and, notably, in a human clinical pharmacokinetic study — a distinguishing feature among research peptides of this class.

Human Pharmacokinetic Data

Cabrales and colleagues conducted a formal pharmacokinetic study in nine healthy male volunteers who received single intravenous bolus doses of GHRP-6 at 100, 200, and 400 mcg/kg of body weight. Using a validated LC-MS/MS method with isotope-labeled internal standard, they determined that GHRP-6 disposition best fitted a bi-exponential (two-compartment) model. The distribution half-life averaged 7.6 +/- 1.9 minutes, reflecting rapid initial tissue distribution, while the elimination half-life averaged 2.5 +/- 1.1 hours. The area under the curve (AUC) increased proportionally with administered dose across the three dose levels, suggesting linear pharmacokinetics within the studied range. Atypical concentration spikes during the elimination phase were observed in four of nine subjects, possibly reflecting enterohepatic recirculation or secondary peptide release.

Absorption and Distribution

GHRP-6 is active via intravenous, subcutaneous, intraperitoneal, and oral routes of administration. The incorporation of D-amino acids at positions 2 and 5 confers substantial resistance to gastrointestinal proteases, enabling oral bioactivity that has been confirmed in both animal models and human studies. Argente and colleagues demonstrated that orally administered GHRPs stimulate GH secretion in humans in a dose-dependent manner, with onset at approximately 15 minutes, peak effect at 60 minutes, and return to baseline by 180 minutes.

Following absorption, GHRP-6 distributes to target tissues including the hypothalamus, pituitary, heart, liver, and gastrointestinal tract. Its relatively small molecular weight (873.01 Da) facilitates tissue penetration, and the D-amino acid substitutions extend its residence time in biological fluids compared to natural peptide sequences of similar length.

Metabolism and Excretion

As a peptide, GHRP-6 is presumed to undergo eventual proteolytic degradation to its constituent amino acids, though the kinetics of this process are substantially slower than for natural L-amino acid peptides of comparable size. The bi-exponential elimination profile observed in human studies, with a terminal half-life of approximately 2.5 hours, is consistent with a combination of renal clearance and tissue metabolism. Detailed metabolite identification studies have not been reported in the peer-reviewed literature.

Research Applications

Growth Hormone Secretion and the GH/IGF-I Axis

GHRP-6’s most extensively characterized research application is as a potent stimulator of GH secretion. In both animal models and human subjects, GHRP-6 produces robust, dose-dependent GH release that is more potent than equimolar doses of GHRH when administered intravenously. The hallmark pharmacological feature of GHRP-6 is its striking synergy with GHRH: co-administration of the two peptides produces GH responses that significantly exceed the arithmetic sum of their individual effects. As documented by Popovic and colleagues, this synergy is mediated at the hypothalamic level and requires an intact hypothalamopituitary connection.

Garcia-San Frutos and colleagues investigated the role of GH secretagogues in reversing age-related decline in the GH/IGF-I axis. They demonstrated that GHRP-6 treatment in aged rats restored GH and IGF-I secretion and liver IGF-I mRNA levels to values comparable to those of young untreated animals, while partially restoring diminished pituitary GH content. These findings suggest that the aging-associated decline in the GH/IGF-I axis may be amenable to pharmacological rejuvenation through GHS-R1a agonism.

Appetite Stimulation and Orexigenic Activity

GHRP-6 is one of the most potent orexigenic (appetite-stimulating) compounds in the GH secretagogue family. Lawrence and colleagues demonstrated that intracerebroventricular injection of GHRP-6 significantly stimulated food intake in rats and activated multiple hypothalamic appetite centers, including the arcuate nucleus, paraventricular nucleus, dorsomedial nucleus, and lateral hypothalamus, as well as brainstem regions (nucleus of the tractus solitarius and area postrema). Critically, the neuronal activation pattern was independent of food intake itself, as identical c-Fos expression patterns were observed in animals denied access to food following GHRP-6 treatment. The orexigenic effect was blocked by pre-administration of a Y1 NPY receptor antagonist, implicating neuropeptide Y signaling as a downstream mediator. Double-immunohistochemistry revealed that GHRP-6 selectively activated orexin-containing, but not melanin-concentrating hormone-containing, neurons in the lateral hypothalamus.

Cardioprotection

A substantial body of evidence, largely generated by the Cuban research group led by Jorge Berlanga-Acosta, has established GHRP-6 as a potent cardioprotective agent. In a landmark study using a porcine model of acute myocardial infarction (left circumflex artery occlusion for 1 hour followed by 72 hours of reperfusion), Berlanga and colleagues demonstrated that GHRP-6 pre-treatment at 400 mcg/kg reduced infarct mass by 78% and infarct thickness by 50% compared to saline controls. More than 50% of GHRP-6-treated animals showed no pathological Q waves on electrocardiography, and serum CK-MB and C-reactive protein levels were significantly reduced. The cardioprotective mechanism was attributed primarily to antioxidant effects, with GHRP-6 decreasing reactive oxygen species (ROS) production while preserving endogenous antioxidant defense systems. Notably, myocardial IGF-I transcription was not amplified by GHRP-6 treatment, suggesting that the cardioprotective effect is independent of the GH/IGF-I axis.

Prevention of Multiple Organ Failure

Cibrian and colleagues extended the cytoprotective research to a model of multiple organ failure (MOF) induced by hepatic ischemia/reperfusion. They demonstrated that GHRP-6 pre-treatment at 120 mcg/kg intraperitoneally caused a 3-fold increase in intestinal epithelial cell migration rate in vitro and reduced hepatic, intestinal, pulmonary, and renal damage by 50-85% in vivo following ischemia/reperfusion injury. The protective effects were associated with reduced neutrophilic infiltration (decreased myeloperoxidase activity) and attenuated lipid peroxidation (reduced malondialdehyde levels). An additional benefit was observed when GHRP-6 was combined with epidermal growth factor (EGF).

Wound Healing and Anti-Fibrotic Effects

GHRP-6 has been investigated as a wound healing agent with unique anti-fibrotic properties. Mendoza Mari and colleagues studied topical GHRP-6 application (400 mcg/mL in carboxymethylcellulose jelly) in both a rat full-thickness excisional wound model and a rabbit ear hypertrophic scar model. In the rat wounds, GHRP-6 attenuated immunoinflammatory mediators and reduced the expression of fibrotic cytokines. In the rabbit hypertrophic scar model, GHRP-6 dramatically reduced the onset of exuberant scars by activating PPARgamma and downregulating fibrogenic cytokine expression. These anti-fibrotic effects are mediated through the CD36 receptor, which is abundantly represented in cutaneous wound granulation tissue. Importantly, GHRP-6 showed no effect on the reversion of already-consolidated fibrotic lesions, indicating that its therapeutic window is during the active inflammatory and proliferative phases of wound healing rather than in established scars.

Neuroprotection

GHRP-6 demonstrates significant neuroprotective properties that extend beyond its ability to elevate circulating GH and IGF-I levels. Delgado-Rubin de Celix and colleagues demonstrated that chronic systemic GHRP-6 treatment in adult rats increased IGF-I levels in the hypothalamus and cerebellum, activated anti-apoptotic signaling cascades (including decreased basal cell death), and reversed glutamate-induced excitotoxicity by decreasing activation of caspases 9 and 7 and reducing PARP fragmentation.

In follow-up studies using the fetal hypothalamic neuronal cell line RCA-6, the same group demonstrated that GHRP-6 neuroprotection against glutamate excitotoxicity is caspase-independent and operates through a distinct pathway involving interference with the translocation of apoptosis-inducing factor (AIF) to the nucleus, associated with the induction of Bcl-2 expression. This effect was independent of IGF-I signaling, establishing a direct neuroprotective mechanism for GHRP-6 through the ghrelin receptor.

Del Barco and colleagues further explored GHRP-6’s neuroprotective potential in a mouse model of proximal axonopathy (induced by 1,2-diacetylbenzene) that reproduces features of amyotrophic lateral sclerosis (ALS). While GHRP-6 alone produced limited improvement, the combined treatment of GHRP-6 with EGF produced significant improvements in behavioral parameters (muscle strength, extensor reflex, spontaneous activity, gait pattern) and electrophysiological recovery, suggesting that combinatorial peptide approaches may represent a viable neuroprotective strategy.

Safety Profile

GHRP-6 has been administered to both animal models and human subjects with a generally favorable safety profile across the published literature.

Human Safety Data

In the pharmacokinetic study by Cabrales and colleagues, single intravenous doses of GHRP-6 at 100, 200, and 400 mcg/kg were well tolerated in nine healthy male volunteers. The most commonly reported acute effects in human GH-releasing studies include transient facial flushing, mild increase in appetite, and transient cortisol elevation. No serious adverse events have been reported in the published human GHRP-6 literature.

Preclinical Safety

In animal models, GHRP-6 has been administered at doses ranging from 100 mcg/kg to 1 mg/kg daily for periods extending up to several weeks without reports of significant organ toxicity. The cytoprotective studies by Berlanga, Cibrian, and colleagues employed doses of 120-400 mcg/kg without adverse histopathological findings in non-target organs.

Hormonal Considerations

Because GHRP-6 stimulates the release of GH, ACTH, cortisol, and prolactin, researchers should be aware of the potential for neuroendocrine effects that may confound experimental endpoints. The cortisol and prolactin responses are generally transient and modest relative to the GH response. Chronic administration may lead to desensitization of the GH response, though this effect is less pronounced with pulsatile than with continuous dosing paradigms.

Known Interactions

GHRP-6 produces a potent synergistic effect with GHRH on GH release, and this interaction should be accounted for in experimental designs involving the hypothalamic-pituitary-GH axis. The GH response to GHRP-6 is attenuated by somatostatin, which inhibits both the direct pituitary and the hypothalamic components of GHRP-6 action. The GHS-R1a antagonist [D-Lys3]-GHRP-6 blocks GHRP-6 effects mediated through the ghrelin receptor but does not inhibit CD36-mediated cytoprotective pathways.

Dosing in Research

The following table summarizes dosing parameters from key published GHRP-6 studies across various experimental models and species.

Molecular Properties

Storage and Handling

For optimal stability in research settings, lyophilized GHRP-6 should be stored at -20 degrees Celsius, where it remains stable for extended periods (typically 2 or more years when kept sealed and desiccated). Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), solutions should be stored at 2-8 degrees Celsius and used within 30 days. Repeated freeze-thaw cycles should be avoided as these may degrade the peptide structure and reduce bioactivity. For long-term storage of reconstituted material, aliquoting into single-use volumes and freezing at -20 degrees Celsius is recommended.

The lyophilized powder should be protected from light and moisture. Vials should be allowed to equilibrate to room temperature before opening to prevent moisture condensation on the peptide cake. When reconstituting, direct the solvent stream against the vial wall rather than directly onto the peptide cake. Gently swirl — do not vortex — until fully dissolved. Typical reconstitution concentrations range from 1-5 mg/mL in bacteriostatic water. A clear, colorless solution with no visible particulates indicates successful reconstitution.

Current Research Landscape

GHRP-6 remains a compound of active research interest across multiple biomedical disciplines. Several key areas represent the current frontiers of investigation:

1. Clinical development of cytoprotective applications: The extensive preclinical evidence for GHRP-6’s cardioprotective, hepatoprotective, and organ-protective properties has generated significant interest in clinical translation. The Cuban biotechnology sector, led by the Center for Genetic Engineering and Biotechnology (CIGB), has been particularly active in developing GHRP-6-based therapeutic formulations for ischemia/reperfusion injury and wound healing applications.

2. Combinatorial peptide therapies: The demonstrated synergistic effects of GHRP-6 with EGF in neuroprotection and organ protection models have spurred research into multi-peptide therapeutic strategies. Subiros and colleagues established dose-response relationships and therapeutic time windows for co-administration of rhEGF and GHRP-6 in a stroke model, finding that the combination administered up to 4 hours following the ischemic insult significantly improved survival and neurological outcome.

3. Aging and the GH/IGF-I axis: The ability of GHRP-6 to restore GH and IGF-I levels in aged animals to those of young adults has renewed interest in GH secretagogues as potential interventions for age-related somatopause. Unlike exogenous GH administration, GHRP-6 preserves the pulsatile pattern of endogenous GH secretion, which is considered physiologically advantageous.

4. Anti-fibrotic mechanisms: The demonstration that GHRP-6 activates PPARgamma through CD36 agonism to attenuate fibrosis opens potential research applications in hepatic fibrosis, pulmonary fibrosis, and other fibrotic conditions where CD36 is expressed. This represents a mechanistic pathway that is entirely independent of the peptide’s GH-releasing activity.

5. Ghrelin system pharmacology: As the original synthetic agonist that led to the discovery of both the GHS receptor and ghrelin, GHRP-6 continues to serve as a fundamental pharmacological tool for investigating ghrelin system biology, including the roles of constitutive GHS-R1a signaling, ghrelin-independent receptor activity, and the complex interactions between the ghrelin and GHRH systems in GH regulation.

References

The studies referenced throughout this monograph represent a subset of the published literature on GHRP-6. For a comprehensive bibliography, researchers are encouraged to search PubMed and Google Scholar using the terms “GHRP-6,” “growth hormone releasing peptide-6,” or “growth hormone secretagogue” for the most current publications. The ghrelin system literature, which originated from GHRP-6 pharmacology, now encompasses thousands of publications across endocrinology, cardiology, neuroscience, and immunology.